Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3356 |
|
| Actual shortage: | 218 (6%) | |
| Anticipated shortage: | 0 (0%) | |
| Avoided shortage: | 10 (0%) | |
| Resolved: | 3128 (93%) | |
Discontinuation Reports |
359 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 335 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
144 (4%) |
|
Overdue reports |
62 (26%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-ONDANSETRON | 4MG | TABLET | Resolved | 2022-02-04 | 2022-02-28 | 154184 |
| APO-ONDANSETRON | 8MG | TABLET | Resolved | 2018-03-13 | 2018-09-29 | 42697 |
| APO-ONDANSETRON | 4MG | TABLET | Resolved | 2023-07-21 | 2024-03-01 | 199536 |
| APO-ONDANSETRON | 8MG | TABLET | Resolved | 2019-06-05 | 2019-11-11 | 85604 |
| APO-ONDANSETRON | 4MG | TABLET | Resolved | 2019-08-07 | 2019-11-11 | 91094 |
| APO-ONDANSETRON | 8MG | TABLET | Resolved | 2019-08-07 | 2019-11-11 | 91097 |
| APO-ONDANSETRON | 4MG | TABLET | Resolved | 2017-12-14 | 2018-09-28 | 32822 |
| APO-ONDANSETRON | 4MG | TABLET | Resolved | 2018-01-08 | 2018-09-29 | 35223 |
| APO-ONDANSETRON | 4MG | SOLUTION | Resolved | 2022-03-07 | 2022-07-15 | 156214 |
| APO-ONDANSETRON | 4MG | TABLET | Resolved | 2022-11-04 | 2022-12-05 | 173818 |
| APO-ONDANSETRON | 4MG | TABLET | Resolved | 2025-02-20 | 2025-02-28 | 250938 |
| APO-OXAPROZIN | 600MG | TABLET | Actual shortage | 2017-03-10 | 2017-10-05 | 411 |
| APO-OXAZEPAM | 10MG | TABLET | Resolved | 2022-07-22 | 2022-09-23 | 165329 |
| APO-OXCARBAZEPINE | 600MG | TABLET | Resolved | 2022-03-25 | 2022-05-25 | 157311 |
| APO-OXCARBAZEPINE | 150MG | TABLET | Resolved | 2024-02-09 | 2024-05-10 | 219159 |
| APO-OXCARBAZEPINE | 300MG | TABLET | Resolved | 2024-04-05 | 2024-05-10 | 224598 |
| APO-OXCARBAZEPINE | 600MG | TABLET | Resolved | 2020-06-10 | 2022-02-09 | 117395 |
| APO-OXCARBAZEPINE | 150MG | TABLET | Resolved | 2020-06-17 | 2022-02-09 | 118043 |
| APO-OXCARBAZEPINE | 300MG | TABLET | Resolved | 2020-06-17 | 2022-02-09 | 118046 |
| APO-OXYBUTYNIN | 5MG | TABLET | Actual shortage | 2025-03-07 | 2025-03-07 | 252151 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60335 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |